StratDeck

Two stocks in Healthcare

Gerresheimer vs UCB: profit, growth, debt and price compared

UCB is stronger on 5 of 6 figures: profit margin, sales growth, debt, analysts' view and price trend. Gerresheimer is stronger on 1: price for its expected profit.

Figures as of 18 November 2026Yahoo Finance

Save both stocks to your watchlist and revisit their latest fundamentals.

Gerresheimer and UCB side by side
GerresheimerGXI.DEUCBUCB.BR
Net margin−17.5%Stronger: 25.7%
Revenue growth, past year−0.80%Stronger: +22.50%
Debt to equity236.7%Stronger: 30.8%
Forward P/EStronger: 13.5×19.1×
Dividend yield—0.51%
AnalystsHold · 12Stronger: Buy · 19
From its 200-day average+13.7%Stronger: +19.9%

Share price over the past year

  • Gerresheimer+36.7%
  • UCB+20.8%

24 Nov 202518 Nov 2026

Gerresheimer or UCB: which is stronger?

  • UCB.BR

    Which is more profitable?

    UCB keeps more of each sale as profit: 25.7% against −17.5%.

  • UCB.BR

    Which is growing its sales faster?

    UCB is growing its sales faster: +22.50% over the past year, against −0.80%.

  • UCB.BR

    Which has borrowed less?

    UCB has borrowed less: its debt is 30.8% of what its shareholders own, against 236.7% for Gerresheimer.

  • GXI.DE

    Which costs less for the profit it is expected to make?

    Gerresheimer costs less for the profit it is expected to make: 13.5× its forward earnings, against 19.1×.

  • Which pays more in dividends?

    UCB pays 0.51% a year in dividends for what a share costs, where Gerresheimer pays none.

  • UCB.BR

    Which do analysts rate higher?

    Analysts are warmer on UCB: Buy, against Hold for Gerresheimer.

  • UCB.BR

    Which is in the stronger price trend?

    UCB's price is in the stronger trend: 19.9% above its 200-day average, against 13.7% above.

What each company does

GXI.DEGerresheimer

Gerresheimer AG, together with its subsidiaries, provides drug containment solutions in Germany and internationally.

Reports results on 25 November 2026

UCB.BRUCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.

Reports results on 25 February 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every European healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.